This study aims to generate structured patient preference evidence on prophylactic treatment options for haemophilia A for adults with and without inhibitors to support health technology assessment and benefit evaluation processes. The study will examine how individuals with haemophilia A evaluate trade-offs between treatment effectiveness, safety, and treatment administration characteristics when choosing between prophylactic therapies. Participants will repeatedly choose between hypothetical treatment profiles that differ in clinically relevant attributes and levels.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
* Participant has the mental capacity and sufficient German language proficiency to understand the study procedures and to complete the survey.
* Age above or equal to 18 years at the time of signing informed consent.
* Validated diagnose with haemophilia A, with and without inhibitors.
* Resident in Germany.
Exclusion Criteria:
* No provision of informed consent in this study.
* Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
* Age below 18 years at the time of signing informed consent.
* Absence of a diagnosis of haemophilia A.
* No residence in Germany.
Primary outcome measure(s)
Choice of treatment alternative in discrete choice tasks — Day 1 Categorical
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.